These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28189366)

  • 1. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis.
    van Amerongen G; Kanhai K; Baakman AC; Heuberger J; Klaassen E; Beumer TL; Strijers RLM; Killestein J; van Gerven J; Cohen A; Groeneveld GJ
    Clin Ther; 2018 Sep; 40(9):1467-1482. PubMed ID: 28189366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia].
    Nauck F; Klaschik E
    Schmerz; 2004 Dec; 18 Suppl 2():S26-30. PubMed ID: 23570087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Vaney C; Heinzel-Gutenbrunner M; Jobin P; Tschopp F; Gattlen B; Hagen U; Schnelle M; Reif M
    Mult Scler; 2004 Aug; 10(4):417-24. PubMed ID: 15327040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
    Leocani L; Nuara A; Houdayer E; Schiavetti I; Del Carro U; Amadio S; Straffi L; Rossi P; Martinelli V; Vila C; Sormani MP; Comi G
    J Neurol; 2015 Nov; 262(11):2520-7. PubMed ID: 26289497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids in multiple sclerosis: A neurophysiological analysis.
    Vecchio D; Varrasi C; Virgilio E; Spagarino A; Naldi P; Cantello R
    Acta Neurol Scand; 2020 Oct; 142(4):333-338. PubMed ID: 32632918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis.
    Gajofatto A
    Mult Scler Relat Disord; 2016 Jul; 8():64-5. PubMed ID: 27456876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial.
    Wissel J; Haydn T; Müller J; Brenneis C; Berger T; Poewe W; Schelosky LD
    J Neurol; 2006 Oct; 253(10):1337-41. PubMed ID: 16988792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
    Lorente Fernández L; Monte Boquet E; Pérez-Miralles F; Gil Gómez I; Escutia Roig M; Boscá Blasco I; Poveda Andrés JL; Casanova-Estruch B
    Neurologia; 2014 Jun; 29(5):257-60. PubMed ID: 24035293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
    Zajicek J; Fox P; Sanders H; Wright D; Vickery J; Nunn A; Thompson A;
    Lancet; 2003 Nov; 362(9395):1517-26. PubMed ID: 14615106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Killestein J; Hoogervorst EL; Reif M; Kalkers NF; Van Loenen AC; Staats PG; Gorter RW; Uitdehaag BM; Polman CH
    Neurology; 2002 May; 58(9):1404-7. PubMed ID: 12011290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Basinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials.
    Prieto González JM; Vila Silván C
    Expert Rev Neurother; 2021 Jul; 21(7):755-778. PubMed ID: 34092180
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C; Davies P; Mutiboko IK; Ratcliffe S;
    Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
    Zajicek JP; Hobart JC; Slade A; Barnes D; Mattison PG;
    J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1125-32. PubMed ID: 22791906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Moreno Torres I; Sanchez AJ; Garcia-Merino A
    Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
    Ferrè L; Nuara A; Pavan G; Radaelli M; Moiola L; Rodegher M; Colombo B; Keller Sarmiento IJ; Martinelli V; Leocani L; Martinelli Boneschi F; Comi G; Esposito F
    Neurol Sci; 2016 Feb; 37(2):235-42. PubMed ID: 26474875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
    Notcutt W; Langford R; Davies P; Ratcliffe S; Potts R
    Mult Scler; 2012 Feb; 18(2):219-28. PubMed ID: 21878454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.